1. Home
  2. TC vs MGNX Comparison

TC vs MGNX Comparison

Compare TC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TuanChe Limited

TC

TuanChe Limited

HOLD

Current Price

$1.55

Market Cap

247.8M

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.67

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TC
MGNX
Founded
2010
2000
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
247.8M
220.6M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
TC
MGNX
Price
$1.55
$4.67
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
9.7K
1.2M
Earning Date
03-28-2025
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$1.26
52 Week High
$19.99
$5.08

Technical Indicators

Market Signals
Indicator
TC
MGNX
Relative Strength Index (RSI) 13.07 62.12
Support Level $0.53 $1.49
Resistance Level $11.40 N/A
Average True Range (ATR) 1.06 0.33
MACD -0.53 0.05
Stochastic Oscillator 0.98 70.08

Price Performance

Historical Comparison
TC
MGNX

About TC TuanChe Limited

Token Cat Ltd has two reportable business segments: automotive electronics resale business and advertising business. The automotive electronics resale business focuses on sourcing, holding, and reselling automotive electronics products, and includes sales of automotive electronic component equipment and accessories, mainly consisting of communication device and power module. The Company procures products from third-party suppliers and resells them to customers through its sales channels. The advertising business currently consists mainly of proxy advertising services, through which the Company helps clients promote their brands, services and products on third-party online platforms. The automotive electronics resale business segment generates maximum revenue.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: